New Data Reinforces Impact of Novartis' Gene Therapy on SMA

Novartis released new data Monday from its Phase III SPR1NT trial that reinforces the benefits of Zolgensma. The company stated that the therapy “demonstrated that children with three copies of the SMN2 back-up gene who were treated presymptomatically achieved age-appropriate motor milestones, including standing and walking.”